Combined pharmacological therapy and temporary use of a wearable cardioverter‐defibrillator decreased arrhythmias during pregnancy in a patient with Andersen–Tawil syndrome.
Does combined pharmacological therapy and a wearable cardioverter-defibrillator safely manage arrhythmias and improve outcomes in a pregnant patient with Andersen-Tawil syndrome?
Combined pharmacological therapy and temporary wearable cardioverter-defibrillator use may represent a safe and effective perinatal management strategy in high-risk pregnancies complicated by Andersen-Tawil syndrome.
Absolute Event Rate: 0% vs 0%
ABSTRACT Andersen–Tawil syndrome (ATS), also known as congenital long QT syndrome type 7 (LQT7), is a rare inherited channelopathy caused by KCNJ2 mutations and characterized by ventricular arrhythmias, periodic paralysis, and dysmorphic features. Pregnancy in women with ATS is extremely uncommon, and optimal perinatal management strategies are not well defined. We describe a 38‐year‐old primigravida with genetically confirmed ATS (p.R228X) who presented at 31 weeks of gestation without medication. During pregnancy, the burden of premature ventricular contractions and non‐sustained ventricular tachycardia decreased compared with the pre‐pregnancy period. At 36 weeks, atenolol and flecainide were introduced, and a wearable cardioverter‐defibrillator (WCD) was applied, further reducing arrhythmias. A planned cesarean section at 37 weeks was uneventful, with favorable maternal and fetal outcomes. Postpartum, arrhythmias increased again, highlighting the importance of surveillance. This case demonstrates that combined pharmacological therapy and temporary WCD use may represent a safe and effective perinatal management strategy in high‐risk pregnancies complicated by ATS.
Sakaguchi 等 (Thu,) 报告了其他情况。结合药物治疗和暂时使用可穿戴心脏复律除颤器减少了患有 Andersen–Tawil 综合症的孕妇在怀孕期间的心律失常。